Godwin Tembo

Blantyre, S, Malawi

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Acceptability of advanced Controlled Human Infection Models: The case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi.

Acceptability of advanced Controlled Human Infection Models: The case of a pneumococcal challenge in people living with HIV and mycobacterial challenge with Bacillus Calmette Guerin in Malawi.

Journal: PLOS global public health

Published: March 20, 2026

Whole cell inactivated poly-bacterial preparation MV130 effect on nasal mucosal immunity and experimental human pneumococcal carriage: double-blind randomised controlled trial with controlled human infection model.

Whole cell inactivated poly-bacterial preparation MV130 effect on nasal mucosal immunity and experimental human pneumococcal carriage: double-blind randomised controlled trial with controlled human infection model.

Journal: EBioMedicine

Published: March 13, 2026

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.

Journal: Vaccine

Published: November 07, 2025

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Pooled analysis of PCV13 efficacy from controlled human infection trials in Malawi and the UK.

Journal: NPJ vaccines

Published: February 25, 2025

Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage at 1-year post-vaccination on rechallenge with Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a controlled human infection study and longitudinal follow-up of a randomised controlled trial.

Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage at 1-year post-vaccination on rechallenge with Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a controlled human infection study and longitudinal follow-up of a randomised controlled trial.

Journal: The Lancet. Microbe

Published: December 11, 2024

Association of mucosal neutrophil inflammation and cytokine responses with natural and experimental pneumococcal carriage in a randomised vaccine trial using experimental human pneumococcal carriage.

Association of mucosal neutrophil inflammation and cytokine responses with natural and experimental pneumococcal carriage in a randomised vaccine trial using experimental human pneumococcal carriage.

Journal: Clinical immunology (Orlando, Fla.)

Published: October 29, 2024

Natural Carriage of Streptococcus pneumoniae Is Associated With Increased Experimental Pneumococcal Carriage but Reduced Conjugate Vaccine Efficacy in a Human Challenge Model.

Natural Carriage of Streptococcus pneumoniae Is Associated With Increased Experimental Pneumococcal Carriage but Reduced Conjugate Vaccine Efficacy in a Human Challenge Model.

Journal: The Journal of infectious diseases

Published: February 15, 2024

Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.

Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.

Journal: Vaccine

Published: November 10, 2023

Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage of Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a randomised controlled trial and controlled human infection study.

Effect of 13-valent pneumococcal conjugate vaccine on experimental carriage of Streptococcus pneumoniae serotype 6B in Blantyre, Malawi: a randomised controlled trial and controlled human infection study.

Journal: The Lancet. Microbe

Published: December 13, 2022

AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.

AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2.

Journal: BMC medicine

Published: February 02, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026